148 related articles for article (PubMed ID: 14977214)
1. Kynurenines in neurodegenerative disorders: therapeutic consideration.
Klivényi P; Toldi J; Vécsei L
Adv Exp Med Biol; 2004; 541():169-83. PubMed ID: 14977214
[No Abstract] [Full Text] [Related]
2. Tryptophan metabolites and brain disorders.
Stone TW; Mackay GM; Forrest CM; Clark CJ; Darlington LG
Clin Chem Lab Med; 2003 Jul; 41(7):852-9. PubMed ID: 12940508
[TBL] [Abstract][Full Text] [Related]
3. Substrate and inhibitor specificity of kynurenine monooxygenase from Cytophaga hutchinsonii.
Phillips RS; Anderson AD; Gentry HG; Güner OF; Bowen JP
Bioorg Med Chem Lett; 2017 Apr; 27(8):1705-1708. PubMed ID: 28302400
[TBL] [Abstract][Full Text] [Related]
4. Manipulation with kynurenines: a possible tool for treating neurodegenerative diseases?
Vecsei L; Plangar I; Szalardy L
Expert Rev Clin Pharmacol; 2012 Jul; 5(4):351-3. PubMed ID: 22943114
[No Abstract] [Full Text] [Related]
5. Kynurenines in the CNS: from endogenous obscurity to therapeutic importance.
Stone TW
Prog Neurobiol; 2001 Jun; 64(2):185-218. PubMed ID: 11240212
[TBL] [Abstract][Full Text] [Related]
6. Kynurenines in the CNS: recent advances and new questions.
Vécsei L; Szalárdy L; Fülöp F; Toldi J
Nat Rev Drug Discov; 2013 Jan; 12(1):64-82. PubMed ID: 23237916
[TBL] [Abstract][Full Text] [Related]
7. The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection.
Vamos E; Pardutz A; Klivenyi P; Toldi J; Vecsei L
J Neurol Sci; 2009 Aug; 283(1-2):21-7. PubMed ID: 19268309
[TBL] [Abstract][Full Text] [Related]
8. Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism.
Török N; Majláth Z; Fülöp F; Toldi J; Vécsei L
Curr Drug Metab; 2016; 17(5):412-29. PubMed ID: 26694727
[TBL] [Abstract][Full Text] [Related]
9. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Tan L; Yu JT; Tan L
J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
[TBL] [Abstract][Full Text] [Related]
10. Neurodegeneration in Multiple Sclerosis: Symptoms of Silent Progression, Biomarkers and Neuroprotective Therapy-Kynurenines Are Important Players.
Sandi D; Fricska-Nagy Z; Bencsik K; Vécsei L
Molecules; 2021 Jun; 26(11):. PubMed ID: 34198750
[TBL] [Abstract][Full Text] [Related]
11. Kynurenines and Multiple Sclerosis: The Dialogue between the Immune System and the Central Nervous System.
Rajda C; Majláth Z; Pukoli D; Vécsei L
Int J Mol Sci; 2015 Aug; 16(8):18270-82. PubMed ID: 26287161
[TBL] [Abstract][Full Text] [Related]
12. The role of kynurenines in the pathomechanism of amyotrophic lateral sclerosis and multiple sclerosis: therapeutic implications.
Füvesi J; Rajda C; Bencsik K; Toldi J; Vécsei L
J Neural Transm (Vienna); 2012 Feb; 119(2):225-34. PubMed ID: 22258797
[TBL] [Abstract][Full Text] [Related]
13. The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders.
Stone TW; Darlington LG
Br J Pharmacol; 2013 Jul; 169(6):1211-27. PubMed ID: 23647169
[TBL] [Abstract][Full Text] [Related]
14. Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway.
Dounay AB; Tuttle JB; Verhoest PR
J Med Chem; 2015 Nov; 58(22):8762-82. PubMed ID: 26207924
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).
Zádori D; Veres G; Szalárdy L; Klivényi P; Fülöp F; Toldi J; Vécsei L
Expert Opin Ther Pat; 2016 Jul; 26(7):815-32. PubMed ID: 27172114
[TBL] [Abstract][Full Text] [Related]
16. Deciphering complex mechanisms in neurodegenerative diseases: the advent of systems biology.
Noorbakhsh F; Overall CM; Power C
Trends Neurosci; 2009 Feb; 32(2):88-100. PubMed ID: 19135729
[TBL] [Abstract][Full Text] [Related]
17. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.
Sas K; Robotka H; Toldi J; Vécsei L
J Neurol Sci; 2007 Jun; 257(1-2):221-39. PubMed ID: 17462670
[TBL] [Abstract][Full Text] [Related]
18. Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines.
Zádori D; Klivényi P; Plangár I; Toldi J; Vécsei L
J Cell Mol Med; 2011 Apr; 15(4):701-17. PubMed ID: 21155972
[TBL] [Abstract][Full Text] [Related]
19. Exploiting the Therapeutic Potential of Endogenous Immunomodulatory Systems in Multiple Sclerosis-Special Focus on the Peroxisome Proliferator-Activated Receptors (PPARs) and the Kynurenines.
Fakan B; Szalardy L; Vecsei L
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30669473
[TBL] [Abstract][Full Text] [Related]
20. Kynurenines and the Endocannabinoid System in Schizophrenia: Common Points and Potential Interactions.
Zádor F; Nagy-Grócz G; Kekesi G; Dvorácskó S; Szűcs E; Tömböly C; Horvath G; Benyhe S; Vécsei L
Molecules; 2019 Oct; 24(20):. PubMed ID: 31619006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
